Literature DB >> 6979307

Azthreonam (SQ 26,776), a synthetic monobactam specifically active against aerobic gram-negative bacteria.

R B Sykes, D P Bonner, K Bush, N H Georgopapadakou.   

Abstract

Azthreonam (SQ 26,776) is a synthetic monocyclic beta-lactam antimicrobial agent belonging to the monobactam family (Sykes et al., Nature [London] 291:489-491, 1981), members of which are characterized by having the 2-oxoazetidine-1-sulfonic acid moiety. Azthreonam exhibits a high degree of stability to beta-lactamases and is specifically active against aerobic gram-negative bacteria, including Pseudomonas aeruginosa. Its activity against these organisms was in general equal or superior to that observed with the third-generation cephalosporins, cefotaxime and ceftazidime. Like penicillins and cephalosporins, azthreonam interacts with essential penicillin-binding proteins of gram-negative bacteria. Azthreonam protected mice against experimental infections produced by a range of gram-negative bacteria, exhibiting efficacy comparable to that of cefotaxime and ceftazidime.

Entities:  

Mesh:

Substances:

Year:  1982        PMID: 6979307      PMCID: PMC181833          DOI: 10.1128/AAC.21.1.85

Source DB:  PubMed          Journal:  Antimicrob Agents Chemother        ISSN: 0066-4804            Impact factor:   5.191


  13 in total

Review 1.  Plasmid-mediated beta-lactamases of Gram-negative bacteria: properties and distribution.

Authors:  M Matthew
Journal:  J Antimicrob Chemother       Date:  1979-07       Impact factor: 5.790

2.  Purification of beta-lactamases on QAE-sephadex.

Authors:  G W Ross; M G Boulton
Journal:  Biochim Biophys Acta       Date:  1973-06-06

3.  A film detection method for tritium-labelled proteins and nucleic acids in polyacrylamide gels.

Authors:  W M Bonner; R A Laskey
Journal:  Eur J Biochem       Date:  1974-07-01

4.  The direct linear plot. A new graphical procedure for estimating enzyme kinetic parameters.

Authors:  R Eisenthal; A Cornish-Bowden
Journal:  Biochem J       Date:  1974-06       Impact factor: 3.857

5.  Cleavage of structural proteins during the assembly of the head of bacteriophage T4.

Authors:  U K Laemmli
Journal:  Nature       Date:  1970-08-15       Impact factor: 49.962

6.  The use of analytical isoelectric focusing for detection and identification of beta-lactamases.

Authors:  A Mathew; A M Harris; M J Marshall; G W Ross
Journal:  J Gen Microbiol       Date:  1975-05

7.  A direct spectrophotometric assay and determination of Michaelis constants for the beta-lactamase reaction.

Authors:  A Samuni
Journal:  Anal Biochem       Date:  1975-01       Impact factor: 3.365

Review 8.  The beta-lactamases of gram-negative bacteria and their role in resistance to beta-lactam antibiotics.

Authors:  R B Sykes; M Matthew
Journal:  J Antimicrob Chemother       Date:  1976-06       Impact factor: 5.790

9.  Preparation of gram quantities of a purified R-factor-mediated penicillinase from Escherichia coli strain W3310.

Authors:  J Melling; G K Scott
Journal:  Biochem J       Date:  1972-11       Impact factor: 3.857

10.  Penicillin-binding proteins in bacteria.

Authors:  N H Georgopapadakou; F Y Liu
Journal:  Antimicrob Agents Chemother       Date:  1980-07       Impact factor: 5.191

View more
  104 in total

1.  Cloning and biochemical characterization of FOX-5, an AmpC-type plasmid-encoded beta-lactamase from a New York City Klebsiella pneumoniae clinical isolate.

Authors:  A M Queenan; S Jenkins; K Bush
Journal:  Antimicrob Agents Chemother       Date:  2001-11       Impact factor: 5.191

2.  The extended-spectrum K1 beta-lactamase from Klebsiella oxytoca SC 10,436 is a member of the bla(OXY-2) family of chromosomal Klebsiella enzymes.

Authors:  Sophie A Granier; Véronique Leflon-Guibout; Marie-Hélène Nicolas-Chanoine; Karen Bush; Fred W Goldstein
Journal:  Antimicrob Agents Chemother       Date:  2002-06       Impact factor: 5.191

3.  In vitro activities of the potent, broad-spectrum carbapenem MK-0826 (L-749,345) against broad-spectrum beta-lactamase-and extended-spectrum beta-lactamase-producing Klebsiella pneumoniae and Escherichia coli clinical isolates.

Authors:  J Kohler; K L Dorso; K Young; G G Hammond; H Rosen; H Kropp; L L Silver
Journal:  Antimicrob Agents Chemother       Date:  1999-05       Impact factor: 5.191

4.  Biochemical characterization of beta-lactamases Bla1 and Bla2 from Bacillus anthracis.

Authors:  Isabel C Materon; Anne Marie Queenan; Theresa M Koehler; Karen Bush; Timothy Palzkill
Journal:  Antimicrob Agents Chemother       Date:  2003-06       Impact factor: 5.191

5.  Inhaled aztreonam.

Authors:  Brian P O'Sullivan; Uma Yasothan; Peter Kirkpatrick
Journal:  Nat Rev Drug Discov       Date:  2010-05       Impact factor: 84.694

6.  Aztreonam therapy in experimental meningitis due to Haemophilus influenzae type b and Escherichia coli K1.

Authors:  G H McCracken; Y Sakata; K D Olsen
Journal:  Antimicrob Agents Chemother       Date:  1985-04       Impact factor: 5.191

7.  Aztreonam concentrations in human prostatic tissue.

Authors:  P O Madsen; R Dhruv; L T Friedhoff
Journal:  Antimicrob Agents Chemother       Date:  1984-07       Impact factor: 5.191

8.  Multiply resistant Klebsiella pneumoniae strains from two Chicago hospitals: identification of the extended-spectrum TEM-12 and TEM-10 ceftazidime-hydrolyzing beta-lactamases in a single isolate.

Authors:  P A Bradford; C E Cherubin; V Idemyor; B A Rasmussen; K Bush
Journal:  Antimicrob Agents Chemother       Date:  1994-04       Impact factor: 5.191

9.  Effect of aztreonam on the colon microflora in patients undergoing colorectal surgery.

Authors:  L Kager; B Brismar; A S Malmborg; C E Nord
Journal:  Infection       Date:  1985 May-Jun       Impact factor: 3.553

10.  Efficacy of aztreonam in treatment of experimental syphilis in rabbits.

Authors:  S A Lukehart; S A Baker-Zander; K K Holmes
Journal:  Antimicrob Agents Chemother       Date:  1984-03       Impact factor: 5.191

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.